text:
ShopTalk is available in two versions, one for pediatric cancer patients and one for their siblings. All questions in both versions of the game are written in Spanish as well as in English. Therapists who are interested in obtaining a copy of the game should contact Dr. Wiener directly at email@example.com.
Early Chemo to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
A large study has found that women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose.
The findings, several gynecologic cancer experts said, should influence clinical practice and make clinicians rethink how they monitor patients for recurrence and initiate additional treatments, or salvage therapies. Read more > >
Lung Cancer Screening Leads to High Rates of False PositivesStudy finds that use of computed tomography led to high rates of follow-up testing
Combo Treatment Boosts Survival in Biliary Tract CancersGemcitabine plus cisplatin may be new standard of care for advanced disease
Breast Cancer Drug Helps Patients with Gastric CancerAdding trastuzumab to chemotherapy modestly improved overall survival
HPV Status Can Predict Outcome in Oropharyngeal CancerDetermining HPV status helps predict treatment response and may become routine
Bevacizumab Does Not Prevent Recurrence of Colorectal CancerThe angiogenesis inhibitor delayed but did not prevent recurrence in a phase III trial
Drugs that Inhibit DNA Repair May Treat Advanced Breast CancerResults from two phase II trials of PARP inhibitors show promise
Radiofrequency Ablation Effective Against Barrett EsophagusUsing radio waves to heat and destroy abnormal cells may be an alternative to surgery
Exposure to PCBs In the Home May Increase Risk of Childhood LeukemiaResearchers measured chemical levels in the home and examined risk of ALL
Special Report: Treatment Vaccines for Cancer Perform Well in Clinical TrialsTherapies that boost the immune system's response to tumors may benefit patients with various types of cancer
Spotlight: Making Personalized Cancer Care RoutineTwo medical centers are testing all lung tumors as part of standard care
Featured Clinical Trial: Imaging the Extent of Prostate CancerWill imaging the prostate with carbon-11-acetate PET and 3-tesla MRI improve detection of early prostate cancer?
Community Update: Through Play, Kids and Families Cope with CancerShopTalk, a board game developed by NCI's Dr. Lori Wiener, allows therapists to help people talk through tough issues
Legislative Update
- Senate Appropriations Subcommittee Reviews Proposed FY2010 Budget
Cancer.gov Update
- Tutorial on Targeted Cancer Therapies Available Online
- U.S. and Canada Collaborate on Cancer Control Web Portal
- NCI's Pastan Awarded Feltrinelli Prize for Medicine
- Freedman Named a DCCPS Branch Chief
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.com.
Featured Article
Early Chemo to Prevent Ovarian Cancer Recurrence Fails to Increase Survival
A large study has found that women in remission for ovarian cancer who started chemotherapy to prevent a recurrence based on blood levels of the protein CA125 did not live longer than women who started chemotherapy only after symptoms of the disease arose.
The findings, several gynecologic cancer experts said, should influence clinical practice and make clinicians rethink how they monitor patients for recurrence and initiate additional treatments, or salvage therapies.
In an international, multicenter randomized clinical trial of more than 500 women, survival was identical between women whose treatment for recurrence was initiated based on CA125 levels and those who were treated at the onset of symptoms. CA125 can be an early indicator that their cancer has returned.
The results of the trial were presented Sunday at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando.
Most women diagnosed with advanced ovarian cancer will suffer a relapse after initial treatment, said the trial's lead investigator, Dr. Gordon Rustin from Mount Vernon Cancer Center in the United Kingdom. As a result, many of these women undergo regular blood tests after treatment to monitor CA125. Many women, Dr. Rustin said, become "addicted" to CA125 screening, "and it causes great anxiety."
The results of this trial, he stressed, show that "chemotherapy can be safely delayed until there are signs or symptoms of recurrence."
Women in the trial had achieved complete remission after initial treatment for advanced ovarian cancer. Half were then randomly assigned to receive treatment once their CA125 levels reached more than twice the upper limit of normal levels; the others were not informed of their CA125 levels, and treatment for recurrence was only begun when there were clinical symptoms of relapse.
Women with advanced disease tend to have multiple relapses and undergo repeated rounds of chemotherapy. In this trial, in fact, women in the CA125 arm averaged 12 more rounds of chemotherapy than those in the symptoms arm, 30 rounds versus 18. Women in the CA125 arm also began second-line chemotherapy 4.8 months earlier than those in the symptoms arm, and third-line chemotherapy 4.6 months earlier.
Because CA125 monitoring has become so ingrained in the treatment of advanced ovarian cancer, this trial "is the kind of research that's very difficult to do," said Dr. Eric Winer, chief of the Division of Women's Cancers at Dana-Farber Cancer Institute, during a press briefing. The results have the potential to improve patients' quality of life, he said.
For women in remission, a doubling of CA125 levels, even if they remain in the normal range, has been shown to herald disease relapse up to 24 months before clinical symptoms appear, said Dr. Beth Karlan, director of the Division of Gynecologic Oncology at Samuel Oschin Comprehensive Cancer Institute, following the presentation of the trial results at the meeting's plenary session.
Even so, she continued, "If early intervention with added chemotherapy does not improve overall survival and may in fact impair [patients'] quality of life, then why are we doing it?"
Because CA125 monitoring leads to more chemotherapy, Dr. Karlan noted, it may worsen cumulative toxicities, and could even impair response to future salvage treatments by hastening resistance to chemotherapy.
However, CA125 monitoring should not become obsolete, she said, noting that clinicians and patients need to be educated about the trial's results. She also recommended less frequent monitoring of CA125 in asymptomatic patients and that clinicians consider delaying palliative chemotherapy until clinical recurrence.
—Carmen Phillips
Cancer Research Highlights
Lung Cancer Screening Leads to High Rates of False Positives
The use of computed tomography (CT) to screen people for lung cancer leads to high rates of false positives, often triggering follow-up tests and invasive procedures, researchers said at the ASCO annual meeting. Concerns about the risks and benefits of lung cancer screening with CT have been raised previously, but this is the first report to quantify the risk of obtaining false-positive results.
Dr. Jennifer M. Croswell of the NIH Office of Medical Applications of Research and her colleagues analyzed data from the Lung Screening Study (LSS), a randomized trial that compared two screening methods—CT and chest x-ray—in more than 3,000 current or former smokers between the ages of 55 and 74. The LSS, which was the feasibility study for the ongoing NCI-sponsored National Lung Screening Trial (NLST), found significantly more false positives in the CT group.
For participants in the CT group, the risk of a false positive was 21 percent after one scan and 33 percent after a second. By comparison, those in the x-ray group had a false-positive risk of 9 percent after one test and 15 percent after two. Because the LSS only included two rounds of screening, Dr. Croswell said, its findings could provide only a conservative estimate of the impact of regular lung cancer screening with CT.
Of those with false-positive results, approximately 60 percent underwent at least one follow-up imaging exam, and slightly less than 2 percent had surgery. Complication rates from these surgeries were low, but a few patients had to be hospitalized for a collapsed lung or blood in the lung (less than 1 percent), and another 1 percent were treated for infections, the researchers said. Additional imaging exams and invasive procedures were also associated with false-positive chest X-rays.
All medical interventions, including screenings, have potential risks as well as potential benefits, the researchers stressed. False positives can create psychological stress and burden the health care system, Dr. Croswell noted.
Combo Treatment Boosts Survival in Biliary Tract Cancers
The combination of cisplatin (Platinal) and gemcitabine (Gemzar) helped patients with advanced, inoperable cancers of the biliary tract (gallbladder and bile duct) live several months longer than patients who received gemcitabine alone (11.7 versus 8.2 months), according to findings presented at the ASCO annual meeting. For patients with these rare but difficult-to-treat cancers, the combination therapy will likely become the new standard treatment, the researchers predicted.
"We consider cisplatin and gemcitabine to now be the worldwide standard of care and the backbone for further studies of patients with advanced biliary tract cancers," lead investigator Dr. Juan Valle of the University of Manchester in the United Kingdom said in a press briefing before the meeting. At the briefing, ASCO President Dr. Richard Schilsky called the study "definitive" and added: "As one who treats these patients in my own clinic, it's very comforting to have a clear standard of care to offer them."
The final-stage ABC-02 trial included 410 patients with advanced biliary tract, gallbladder, or ampullary carcinoma. In addition to improving overall survival, the combination therapy delayed the progression of the disease by 2 months (8.5 versus 6.5 months). In both groups, side effects were similar, although there was a slight increase of neutropenia in patients receiving the combination therapy, the researchers said.
The next steps will involve trying to add some of the newer targeted cancer therapies to the combination and identifying which patients will benefit most from these treatments, noted Dr. Valle. He cautioned that adding another chemotherapy drug could increase toxicity without producing a benefit to patients.
Breast Cancer Drug Helps Patients with Gastric Cancer
The breast cancer drug trastuzumab (Herceptin) has been shown to improve the survival of patients with advanced gastric cancer. The addition of trastuzumab to standard chemotherapy helped patients live longer than similar patients who received chemotherapy alone, researchers said at the ASCO annual meeting.
The phase III ToGA trial compared the two treatments in 594 patients whose tumors showed elevated levels of the protein HER2, which is the target of trastuzumab. Patients who received trastuzumab plus chemotherapy lived 13.8 months, compared with 11.1 months for those who received chemotherapy alone, said lead investigator Dr. Eric Van Cutsem of the University Hospital Gasthuisberg in Leuven, Belgium. The results translate into a 26 percent reduction in the risk of death.
Trastuzumab is the first targeted drug to improve overall survival for patients with gastric cancer in a phase III trial, he said. And while the survival benefit was small, he added, the findings represent a rare advance in gastric cancer.
The combination treatment was well tolerated and there were no unexpected side effects in the trastuzumab group, Dr. Van Cutsem said. The rate of congestive heart failure, which is routinely monitored in trials involving trastuzumab, was similar between the groups. The incidence of decreased ventricular ejection fraction (a measure of the heart's pumping ability) was 5.9 percent in the trastuzumab group compared with 1.1 percent in the chemotherapy-alone group. The reason for the low rate of cardiac effects, he said, may be because trastuzumab was not used in conjunction with anthracycline-based chemotherapy, which is how trastuzumab is often administered to breast cancer patients.
HPV Status Can Predict Outcome in Oropharyngeal Cancer
Patients with advanced forms of a cancer in the upper portion of their throat have better outcomes if their tumors are positive for the human papillomavirus (HPV), according to new data from a phase III clinical trial presented at the ASCO annual meeting. Although other studies have suggested a link between HPV status and outcome in patients who have oropharyngeal cancer, these new data provide the most definitive evidence, said the study's leader, Dr. Maura Gillison of Ohio State University, at a recent press briefing.
Oropharyngeal cancer "can now be divided into those linked to prolonged use of tobacco and alcohol, and those linked to HPV," she said. And determining HPV status, she added, "may now be part of routine clinical care…because of its prognostic implications in these patients."
The findings come from a correlative study in the Radiation Therapy Oncology Group (RTOG) 0129 clinical trial, a phase III trial in which patients with stage III or IV oropharyngeal cancer were randomly assigned to receive different regimens of radiotherapy and the chemotherapy drug cisplatin. Nearly two-thirds of the tumor samples tested HPV-positive, Dr. Gillison said. Two years after treatment, 88 percent of the HPV-positive patients were still alive, compared with 66 percent of the HPV-negative patients. The absolute difference in survival increased over time.
Additional analyses ruled out other factors, such as age, performance status, and treatment, which might account for the superior outcomes seen in patients with HPV-positive tumors.
Due to the dramatic differences in treatment response, Dr. Gillison said, from this point forward RTOG and the Eastern Clinical Oncology Group will stratify all of their clinical trials by HPV status, and they will design clinical trials specifically for HPV-positive or -negative patients.
Bevacizumab Does Not Prevent Recurrence of Colorectal Cancer
Adding 1 year of treatment with the targeted drug bevacizumab (Avastin) to standard post-surgery treatment for early stage colorectal cancer failed to improve disease-free survival (the time that patients are free of tumor recurrence) after 3 years of follow up compared to the standard treatment alone, according to results presented at the ASCO annual meeting.
The NCI-supported C-08 trial, led by the National Surgical Adjuvant Breast and Bowel Project (NSABP), was the first phase III trial to report findings using an angiogenesis inhibitor as part of adjuvant therapy for an early stage cancer. Bevacizumab, which blocks blood flow to tumors, is already approved for use in advanced colorectal, breast, and lung cancers.
More than 2,700 stage II and III colorectal cancer patients whose tumors had been surgically removed were randomly assigned to receive either a 6-month course of the standard adjuvant chemotherapy regimen or chemotherapy plus bevacizumab, followed by an additional 6 months of bevacizumab alone. After 3 years, there was little difference in the disease-free survival rate, 75.5 percent versus 77.4 percent, respectively.
There was a statistically significant disease-free survival benefit during the year of active treatment with bevacizumab, stressed the trial's leader, Dr. Norman Wolmark from Allegheny General Hospital in Pittsburgh. In fact, the benefit was nearly strong enough to stop the trial early. But "that efficacy disappeared after bevacizumab was no longer given," he said.
Several recent animal model studies have suggested that, under certain circumstances, angiogenesis inhibitors, after initially shrinking tumors, could make them more aggressive and likely to metastasize. The investigators looked closely at this issue, Dr. Wolmark said, "and we saw absolutely no hint of a harmful rebound effect."
Dr. Axel Grothey, from the Mayo Clinic, agreed that bevacizumab appears to have an effect only during treatment, but that it only seems to delay tumor recurrence, not prevent it. At this point, he stressed, bevacizumab should not be used as an adjuvant treatment outside of a clinical trial.
The NSABP hopes to launch a similar phase III trial in which bevacizumab is given in the adjuvant setting for 2 years, Dr. Wolmark said.
Drugs that Inhibit DNA Repair May Treat Advanced Breast Cancer
A new type of targeted agent that impairs a tumor cell's ability to repair damaged DNA may be beneficial in women with hard-to-treat forms of breast cancer, according to findings from two small clinical trials presented at the ASCO annual meeting.
The phase II trials tested different agents that inhibit an important DNA-repair enzyme in tumor cells called PARP. The larger of the two trials, led by Dr. Joyce O'Shaughnessy from the Baylor Charles A. Sammons Cancer Center in Dallas, tested a PARP inhibitor called BSI-201. One hundred sixteen women with metastatic, "triple-negative" breast cancer (tumors negative for the HER2 protein and estrogen and progesterone receptors), whose disease had progressed despite prior treatment, were randomly assigned to receive chemotherapy with gemcitabine and carboplatin with or without BSI-201.
Women who received the BSI-201 and chemotherapy combination had significantly longer time to progression of their disease, 6.9 months compared with 3.3 months, and longer overall survival, 9.2 months compared with 5.7 months, than women who received chemotherapy alone. Overall survival was a secondary endpoint in the trial, Dr. O'Shaughnessy noted. The drug was "very well tolerated," she said. "We couldn't discern any added toxicity."
In the second trial, Dr. Andrew Tutt from Kings College, London, and his colleagues tested an oral PARP inhibitor called olaparib as a single agent in women with advanced breast cancer whose tumors had mutations in the BRCA1 or BRCA2 genes and whose disease had persisted despite prior treatment.
Because of strong enrollment, the trial was expanded to test two different doses, Dr. Tutt said. The higher dose appeared to be more effective, with 40 percent of women who received the higher dose experiencing tumor shrinkage, compared to 22 percent in women who received the lower dose. The drug had minimal side effects, the most common of which were mild nausea and fatigue.
Bipar Sciences, which manufactures BSI-201, expects to launch a similar phase III trial of the agent this summer. Dr. Tutt said he is in discussions with Astra Zeneca, which manufactures olaparib, to move that agent forward into larger trials.
Radiofrequency Ablation Effective Against Barrett Esophagus
About 10 percent of the 10 million adults in the United States who have chronic gastroesophageal reflux disease develop abnormal cell changes in the lining of their esophagus, a condition called Barrett esophagus (BE) that can lead to esophageal cancer. While 99 percent of adults with BE will not progress to cancer, their risk of developing esophageal cancer is still 100 times greater than that of the general population.
New results published May 27 in the New England Journal of Medicine show that radiofrequency ablation (RFA) may be an effective treatment for BE. Dr. Nicholas J. Shaheen, of the University of North Carolina at Chapel Hill, and his colleagues conducted a trial of 127 BE patients who had either high- or low-grade dysplasia (abnormal cells with precancerous traits) in the lining of their esophagus.
Eighty-four of these patients received the RFA treatment, which involved inserting and then inflating a balloon into the esophagus in an outpatient procedure. Radiofrequency waves heated coils on the balloon's surface to burn away only the layer of affected cells on the esophageal lining. The remaining 43 patients were part of a control group that received a "sham procedure."
Low-grade dysplasia was completely eradicated in 90.5 percent of those receiving RFA, compared with 22.7 percent in the control group. High-grade dysplasia was eradicated in 81 percent of those receiving RFA, compared with 19 percent of controls. While RFA had side effects—transient chest discomfort and occasional narrowing of the esophagus—these were slight compared with those of esophagectomy, a treatment commonly used to treat high-grade dysplastic BE, which has a 3 to 5 percent mortality rate and complications in 40 to 50 percent of patients.
In an accompanying editorial, Dr. Jacques J.G.H.M. Bergman of the Academic Medical Center in Amsterdam said these results "suggest that surgery for high-grade dysplasia should no longer be offered routinely."
Exposure to PCBs in the Home May Increase Risk of Childhood Leukemia
Between 1975 and 2004, the incidence of acute lymphoblastic leukemia (ALL), which occurs more frequently in children than in adults, rose significantly in the United States. Investigators from NCI's Division of Cancer Epidemiology and Genetics (DCEG) and the University of California, Berkeley examined whether residential exposure to polychlorinated biphenyls (PCBs) or organochlorine insecticides such as DDT may increase the risk of ALL. These chemicals were banned in the 1970s but persist in the environment and are still found indoors, especially in older homes. Their findings are published in the June issue of Environmental Health Perspectives.
The researchers identified 203 children aged 7 years or younger living in 35 California counties and diagnosed with leukemia between 2001 and 2006. The children were living in their current home at the time of diagnosis. One hundred eighty four of the children with leukemia had ALL. The children were matched by age, gender, race, Hispanic ethnicity, and county of residence to 212 children who didn't have leukemia.
Carpet dust samples were collected from the rooms where these children spent most of their time while awake in the home, to analyze for the chemicals being studied. Detection of any of the PCBs in the dust samples was associated with a twofold increased risk of ALL, and the risk increased with the concentration of total PCBs. ALL risk was not increased among children from homes with higher concentrations of DDT, chlordane, or the other measured organochlorine insecticides.
However, the researchers observed higher rates of ALL associated with detection of total PCBs and individual PCB types in carpet dust samples from homes of non-Hispanic whites compared with Hispanics and other races. The different results for these ethnic groups could not be explained by different concentrations in the homes or any of the other factors measured in the study.
"The fact that this is the first population-based study to evaluate residential levels of these chemicals and risk of ALL, and that findings were not consistent across ethnic groups, means that we need to use caution in the interpretation," said DCEG lead author Dr. Mary Ward. "These results are interesting, but they need further study."
Special Report
Treatment Vaccines for Cancer Perform Well in Clinical Trials
Treatment vaccines that boost the immune system's response to tumors may have important clinical benefits for patients with various types of cancer, according to results from several clinical trials presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando.
To many in the field, the findings represent an emergence of sorts for therapeutic cancer vaccines. Treatment vaccines have been the subject of intense study for more than 2 decades, but they have produced little in the way of FDA-approved cancer treatments. That could change based on the recent clinical trial results.
"The field has been getting more attention, and with these recent trials I think we'll see a surge of interest in immunotherapy leading to much needed additional therapeutic options that improve survival without significant toxicity," said Dr. James Gulley from NCI's Center for Cancer Research, who is leading a number of clinical trials using treatment vaccines.
Therapeutic cancer vaccines, added Dr. Jeffrey Schlom, chief of NCI's Laboratory of Tumor Immunology and Biology, have had a hard time gaining acceptance in part because they represent a different care paradigm. "A vaccine is the only therapeutic modality that doesn't work on the tumor. It works on the patient's immune system to keep the tumor in check," he said.
Among the results that generated intense interest at the meeting were those from a large, phase III clinical trial of a vaccine called BiovaxID to treat patients with follicular lymphoma, the second most common type of non-Hodgkin lymphoma. Dubbed an idiotype vaccine, BiovaxID is customized for each individual patient from tumor cell proteins taken from tumor biopsies.
The trial, BV301, randomly assigned patients who had a sustained (6-month) complete response to standard chemotherapy to either BiovaxID plus two other immune-stimulating agents (GM-CSF and KLH) or the two immune-stimulating agents alone. Patients who received the vaccine had a 47 percent improvement in progression-free survival (survival without tumor growth) compared to those who only received the immune stimulants, 44.2 months versus 30.6 months, reported lead investigator Dr. Stephen J. Schuster from the University of Pennsylvania School of Medicine.
Two previous phase III trials using a similar vaccine in patients with follicular lymphoma had negative results. That may be because those trials included patients who had partial responses and stable disease, as well as complete responses, explained Dr. Ronald Levy of the Stanford University School of Medicine, during the meeting's plenary session. In contrast, the analysis from BV301 was limited to patients who were "the best of the best"—that is, only those with sustained complete responses.
Drs. Levy and Schuster agreed that it's still unclear how this vaccine would work in the context of the current standard of care for follicular lymphoma, which changed during the course of the BV301 trial and now includes the monoclonal antibody rituximab (Rituxan). Calling the trial a "qualified success," Dr. Levy said other clinical trials will be needed to establish the best use of the vaccine in follicular lymphoma.
Another phase III trial that generated interest at the meeting used a long-studied peptide-based vaccine (a peptide is a small segment of amino acids) to treat patients with metastatic melanoma, a deadly skin cancer for which treatment advances have been rare.
When combined with IL-2, the standard of care for metastatic melanoma, treatment with the gp100:209-217(210M) peptide vaccine doubled the response rate of patients compared to those who received IL-2 alone, 22.1 percent versus 9.7 percent, reported one of the trial's leaders, Dr. Patrick Hwu from the University of Texas M.D. Anderson Cancer Center. Response rate was the trial's primary endpoint. There was a slight improvement in progression-free survival, 2.9 versus 1.6 months, and the preliminary analysis suggests a trend toward improved overall survival.
Calling the improvement an "important finding," Dr. Lynn Schuchter from the University of Pennsylvania's Abramson Cancer Center said the results are grounds for optimism. Therapeutic vaccines have been tested in melanoma for more than a decade with little success. Now there is a positive phase III clinical trial.
"It makes us think maybe this is a combination that will work," she said.
There are a number of other immune stimulating agents under study that can be used in combination with the peptide vaccine, Dr. Hwu said. The next steps, he noted, will be to conduct another large trial to replicate these findings and continue testing different combinations.
In a smaller, phase II clinical trial with 122 patients, treatment with a vaccine developed at NCI, called Prostvac, showed a more than 8-month improvement in overall survival in patients with indolent metastatic prostate cancer. This is the second phase II trial to show a nearly identical benefit of Prostvac, which is comprised of two virus-based "vectors," in the same patient population, explained Dr. Schlom. A larger, phase III trial is expected to begin in 2010.
The field is already moving toward combining different therapeutic vaccines, Dr. Schlom continued, with the idea of using them in earlier-stage disease, where he believes they will be most effective.
—Carmen Phillips
Making Personalized Cancer Care Routine
A small group of oncologists and pathologists from five medical centers gathered last fall to talk about the nuts and bolts of personalizing cancer care. On the table were a host of practical issues related to one big question: Can hospitals routinely use genetic and molecular information from tumors to match patients with the most appropriate drugs in an affordable and timely manner?
The answer to this question may not come for years. But some lessons about what works and what doesn't could emerge much sooner. Massachusetts General Hospital and Memorial Sloan-Kettering Cancer Center (MSKCC) have begun to screen all lung tumors for genetic changes that could reveal whether a particular treatment is likely to work or should be avoided.
"We believe the profiling of tumors will become more and more integrated with clinical practice in the future, and we want to see that happen sooner rather than later," said Dr. Leif Ellisen, an oncologist at Mass General and co-director of a new molecular pathology lab that profiles the tumors. "Most centers realize that this is where the field of oncology is going in terms of directed therapies."
He noted that interest in tumor profiling extends well beyond the centers that met last fall (which also included Dana-Farber Cancer Institute, University of Texas M.D. Anderson Cancer Center, and Vanderbilt Medical Center). In fact, personalizing cancer care is the theme of the American Society of Clinical Oncology (ASCO) Annual Meeting this week in Orlando.
At this stage, however, the approach has some important limitations. For starters, only a fraction of the molecular changes involved in cancer have been identified, and more drugs that target these changes are needed. At MSKCC, nearly half the lung tumors tested do not harbor one of the known gene mutations associated with the disease.
Lung Cancer: A Test Case
Despite the limitations, the current understanding of lung cancer is vastly different from a decade ago, when most tumors were thought to be essentially the same and patients received the same drugs. Today, it's clear that subsets of tumors are driven by gene mutations that activate cancer-promoting signals in cells and, in some cases, drugs are available to block these signals.
"We're nearing a point where patients need not only a diagnosis of lung cancer but also to know the molecular subtype of the tumor," said Dr. Lecia Sequist, who treats patients with lung cancer at Massachusetts General Hospital Cancer Center.
Mutations in the gene EGFR, for instance, tend to make tumors respond to gefitinib (Iressa) or erlotinib (Tarceva). These drugs are pills, taken once a day, that block critical signals in tumors and usually have fewer side effects than chemotherapy. While less than 30 percent of lung cancers in the United States carry the mutations, those that do have a 70 percent chance of responding to the drugs.
The Mass General test profiles 13 genes, including EGFR, that are altered in a variety of cancers. A team led by pathologist Dr. John Iafrate developed a process for automatically extracting DNA from standard tumor specimens and screening the DNA for 120 cancer-related changes. The pathology lab tests about 20 lung tumors per week, a number that will rise as the program is gradually expanded to include all cancer patients.
By making the test broad rather than focused on a single cancer, the researchers hope to pick up mutations that may be rare in one tumor type, but for which a treatment already exists. Some lung tumors have alterations in the gene HER2, for example, and these tumors may respond to the breast cancer drug trastuzumab (Herceptin).
"In our view," said Dr. Ellisen, "medicine isn't personalized if you're only testing patients for the common mutations."
Why Now?
A shift toward personalized care may be happening now because of technologies that can test for multiple genetic changes simultaneously, and also because of growing evidence that patients benefit. For instance, many colorectal cancer patients undergo gene testing before starting on cetuximab (Erbitux) to determine whether they are candidates for the treatment or should be spared the costs and side effects.
"This approach is exactly what the patients want," said Dr. Mark Kris, chief of the Thoracic Oncology Service at MSKCC. "They want to know that we've used all of our resources to analyze their cancers. It's what clinicians want as well—to give patients treatments that are targeted to their particular disease."
Interim results from the IPASS lung cancer trial, presented at the ASCO meeting, underscored the need for tumor testing. The randomized trial compared gefitinib and chemotherapy as a first-line therapy and found that patients with EGFR gene mutations tended to respond better to gefitinib. Other patients fared better with chemotherapy.
The study is relevant to personalized medicine because nearly all the participants fit the profile of someone who may benefit from gefitinib or erlotinib. That is, they were Asian nonsmokers or light smokers. Yet only some of these individuals—those with EGFR mutations—actually benefited from gefitinib.
This finding, Dr. Sequist noted, suggests that patients may need to have their genes tested rather than simply relying on doctors to make an educated guess about who will benefit most from these drugs.
"Incredibly Complicated"
The need to collect tissue samples from patients for testing and the fact that many tumors eventually develop resistance to targeted drugs are among the many challenges facing the new field. Another complication, the researchers said, is that patents on gene mutations in the future could narrow the scope of testing at some institutions.
Nonetheless, valuable lessons may come from the current programs, including how to make personalized cancer care work within the current health care system. The investigators have been sharing their experiences with colleagues, and later this year they plan to publish a summary of the meeting last fall.
"Doing this within the current health care system is unbelievably complicated," said Dr. Kris. "This is not how hospitals work right now, and it is not how oncology is practiced." The investigators need to both "work out the bugs" in the current systems and demonstrate the benefits of this approach to the medical establishment, he added.
"It's not easy," Dr. Kris continued, "but we and the other institutions doing this are all committed to taking this forward and making it the standard of care."
—Edward R. Winstead
Featured Clinical Trial
Imaging the Extent of Prostate Cancer
Name of the Trial
Phase I/II Pilot Study of Carbon-11 Acetate Positron Emission Tomography and 3-Tesla Magnetic Resonance Imaging in Patients with Localized Prostate Cancer Undergoing Prostatectomy (NCI-08-C-0092). See the protocol summary.
Principal Investigator
Dr. Peter Choyke, NCI Center for Cancer Research
Why This Trial Is Important
When doctors suspect a man has prostate cancer, they often use ultrasound to create images of the prostate gland and perform a series of core biopsies to collect samples of prostate tissue. Unfortunately, ultrasound does not provide very detailed images of prostate tumors, and "hit-or-miss" biopsy samples may not reveal the aggressiveness of the cancer. It is important, therefore, to develop more sensitive methods to detect and characterize prostate tumors.
Some other imaging methods, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), offer some benefits in detecting and characterizing prostate cancer, but both of these methods still lack the required level of sensitivity. MRI can help determine the physical boundaries of tumor tissue, but it is not very useful in assessing which parts of the tumor are most actively growing. PET scans using radiolabeled-glucose molecules are capable of revealing areas of rapid cell growth in many tumor types; however, prostate tissue does not readily metabolize glucose, making glucose-based PET scans unreliable for prostate cancer.
In this clinical trial, researchers are testing PET scans using a different radiolabeled molecule, carbon-11 (C-11) acetate, in conjunction with subsequent MRI to see if the resulting images allow better characterization of both the physical extent and the relative level of cellular growth of prostate tumors in patients known to have prostate cancer. Following the imaging tests, the patients will undergo surgery to remove their prostates. The removed prostates will then be examined to assess the accuracy of the imaging scans.
"Detecting cancer when it is still confined to the prostate gland is the key to long survival," said Dr. Choyke. "Unfortunately, current imaging techniques have very poor sensitivity for prostate cancer. Our purpose with this study is to validate the use of both C-11 acetate PET and the latest MRI technology to detect cancer at an early stage.
"This research complements other treatment and diagnostic work at NIH, including research in robotic prostatectomy, image-guided radiotherapy, and minimally invasive radio-diagnostic procedures, making NCI a unique institution for the treatment of prostate cancer," Dr. Choyke added.
For More Information
See the list of entry criteria and trial contact information or call the NCI Clinical Trials Referral Office at 1-888-NCI-1937. The call is toll free and confidential.
Community Update
Through Play, Kids and Families Cope with Cancer
If you could look back and change something that you said or did in your life, what would that be?
It's a difficult question for anyone to answer honestly, not to mention someone who is facing a life-threatening illness. Such a question can be especially difficult for children. But when posed in the atmosphere of play, answering becomes easier.
"Play is really the way to uncover children's feelings and help them explore their inner world, working through some of their fears and helping them find coping strategies," explained Dr. Lori Wiener, head of the psychosocial section in NCI's Pediatric Oncology Branch. She noted that the strategy can work well in some situations for adults, too.
Dr. Wiener developed a workbook to assist children being treated for cancer or HIV infection at NIH with talk therapy sessions, and found the tool to be very successful. She then partnered with Dr. Cindy Mamalian, an artist and psychologist, to develop a prototype board game version of the workbook and began testing it with her patients, gathering their feedback during the revision process.
Nearly 10 years later, the culmination of this project is ShopTalk, a board game that helps therapists lead conversations with pediatric cancer patients and their parents about difficult emotional issues related to the illness that has affected their lives. ShopTalk is the only such therapeutic game designed for children aged 7 to 16 years.
Dr. Wiener has been working with the nonprofit organization SuperSibs to distribute the sibling version of the game, and she has contacted psychosocial oncology programs at hospitals around the country that treat children with cancer. The response from those who are using ShopTalk has been very enthusiastic.
"I have been using the game several times a week since I put it out in my office," said Dr. Rachel Levi, a pediatric clinical psychologist in Oakland, CA. "Uniformly, the feedback has been positive from both me and the kids with whom I've used it."
Other clinical psychologists and professors of pediatric medicine have written to Dr. Wiener with simple notes of "Thank you!" for providing them with such a valuable clinical tool.
Because critical information can be revealed through the course of play—suicidal feelings, for example, or non-adherence to medication regimens—Dr. Wiener stressed that the game should only be used with the supervision of a trained therapist so that opportunities for intervention aren't missed.
ShopTalk players visit 10 different "shops" around the board, choosing one of 6 "gifts" from each store to place in their individual shopping bag when they choose to answer the question. The shops are named according to different themes: The Ball's in Your Court sports store, for example, allows players to explore how they would respond to various social scenarios during treatment.
The added beauty of the game lies in its flexibility. Questions can be very simple, such as, "What is your favorite movie?" or they can be deeper, such as, "Do you think that children with a disease should be disciplined the same as kids who are healthy?" In this way, a therapist can tailor the game to the needs of the players, delving deeper with each round or tailoring the questions to an individual's concerns or needs.
After hearing the question, the player is asked if they would like to buy the gift. If they're not comfortable answering, they can say, "No thanks, just looking." Questions can also be addressed to the entire group of players, allowing the chance for someone who isn't comfortable talking about his or her own problem to learn through the experience of others.
Though it's based on the premise of fun, ShopTalk clearly enters into emotionally charged territory. Dr. Wiener says that it's important for people to talk about the thoughts that keep them awake at night, rather than struggling in silence.
"Many kids who have cancer are concerned about sharing information that will upset their parents," she explained. "But their parents may be having these same thoughts. So they each end up coping in emotional isolation, putting a lot of energy into not thinking about what is troubling them. This game provides them a safe opportunity to find coping strategies together, so that they can focus their energy on healing, rather than avoidance."
Last week, Dr. Wiener played ShopTalk with the family of a child who has cancer during a therapy session. One of the questions asked them to recall events from the day that each of them learned about the diagnosis, more than 4 years ago.
"They all remembered an amazing amount of detail," she explained. "It gave them a chance to correct misperceptions about what had happened and what was said, and each obtained a new awareness about how traumatizing that particular time was for each of them. The conversation wouldn't have happened if we weren't playing the game."
Legislative Update
Senate Appropriations Subcommittee Reviews Proposed FY2010 Budget
On May 21, the Senate Committee on Appropriations' Subcommittee on Labor, Health and Human Services, Education, and Related Agencies held a hearing to examine the President's proposed fiscal year 2010 budget for NIH and to discuss the $10.4 billion provided to NIH in the American Recovery and Reinvestment Act. NIH Acting Director Dr. Raynard Kington, NIAID Director Dr. Anthony Fauci, NHLBI Director Dr. Elizabeth Nabel, and NCI Director Dr. John Niederhuber testified.
Senator Tom Harkin (D-IA), chairman of the Subcommittee, expressed concerns about how Recovery Act funds were being spent and what happens after funding runs out in 2011. Dr. Niederhuber testified that Recovery Act funds were allowing NCI to advance projects in early phase translational research and to expand The Cancer Genome Atlas project to include additional cancer sites, beyond glioblastoma, ovarian cancer, and lung cancer.
Due to the strong interest in the challenge grants, Senator Harkin was concerned that fewer than 5 percent would be funded. Dr. Kington predicted that NIH would more than double its initial commitment of $200 million, allowing the agency to fund a greater number of challenge grants. Dr. Kington also noted that every institute and center at NIH funds research related to cancer, and NIH has initiated a strategic planning process co-chaired by Dr. Niederhuber and Dr. Stephen Katz, director of NIAMS and a senior investigator at NCI.
For more information about this and other NCI congressional activity, visit the NCI Office of Government and Congressional Relations' Web site.
Cancer.gov Update
Tutorial on Targeted Cancer Therapies Available Online
NCI recently added a new tutorial to its Understanding Cancer Series, a collection of educational tutorials for life science teachers, health professionals, and the interested public. Understanding Targeted Therapies for Cancer, the first animated tutorial in the series, provides an overview of this emerging approach to cancer treatment. The tutorial explains the three main types of targeted therapies, their risks and benefits, how they differ from conventional chemotherapy, which targeted therapies are currently FDA-approved, and how one can find clinical trials that are evaluating these new treatment approaches.
View or download Understanding Targeted Therapies for Cancer at www.cancer.gov/cancertopics/understandingcancer/targetedtherapies or contact Donna Kerrigan at firstname.lastname@example.com to request a DVD.
U.S. and Canada Collaborate on Cancer Control Web Portal
In a collaborative effort, NCI and the Canadian Partnership Against Cancer (CPAC) have expanded the Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network with Evidence-based Tools) Web portal from the United States to Canada.
The U.S. Cancer Control P.L.A.N.E.T. Web portal was launched after extensive usability testing in April 2003 by NCI's Division of Cancer Control and Population Sciences in collaboration with the Agency for Healthcare Research and Quality, the American Cancer Society, the Centers for Disease Control and Prevention, the Commission on Cancer, and the Substance Abuse and Mental Health Services Administration. The Canadian site follows the same design as the U.S. site, while engaging Canadian cancer control practitioners and researchers in usability testing to ensure that the Canadian site meets their needs.
Both the Canadian and U.S. sites provide a single point of access to high-quality tools and resources from multiple national organizations, which can be used to design, implement, and evaluate evidence-based cancer control plans and programs.
NCI's Pastan Awarded Feltrinelli Prize for Medicine
Dr. Ira Pastan, chief of the Laboratory of Molecular Biology in NCI's Center for Cancer Research, will receive the 2009 International Antonio Feltrinelli Prize for Medicine, which will be awarded in Rome this June by the Accademia Nazionale dei Lincei. The organization, founded in 1603, is considered Italy's most prestigious scientific society and includes Galileo as an early member. This is the first time an NIH scientist has received the award. Presented every 5 years, the International Antonio Feltrinelli Prize for Medicine includes a gold medal and a monetary prize of 250,000 Euros.
Dr. Pastan's early research focused on understanding the mechanism of action of polypeptide hormones and defining their pathway of entry into the cell. He was among the first to clone and sequence the EGF receptor and demonstrated that it is amplified in many cancers. Realizing that powerful toxins could be targeted to kill specific cells, Dr. Pastan and Dr. David FitzGerald designed and produced novel recombinant immunotoxins that have a cancer-seeking antibody genetically fused to a portion of Pseudomonas exotoxin A. His clinical research group, led by Dr. Robert Kreitman, tested these new treatments in humans and found that BL22 produced a very high rate of complete remissions in patients with drug-resistant hairy cell leukemia.
Freedman Named a DCCPS Branch Chief
Last week, Dr. Andrew N. Freedman was appointed chief of the Clinical and Translational Epidemiology Branch (CTEB) in the Epidemiology and Genetics Research Program in NCI's Division of Cancer Control and Population Sciences (DCCPS).
CTEB supports, directs, and stimulates research on clinical, environmental, and genomic factors that influence cancer progression, recurrence, new primary cancers, and mortality. It also supports and coordinates research on factors that contribute to the development of cancer among individuals with underlying diseases and conditions.
Dr. Freedman earned his Ph.D. in epidemiology from the University of Buffalo and Roswell Park Cancer Institute. He was a postdoctoral research fellow in the Genetic Epidemiology Branch of NCI's Division of Cancer Epidemiology and Genetics before he joined DCCPS in 1997 as a molecular epidemiologist in the Applied Research Program's Risk Factor Monitoring and Methods Branch. Dr. Freedman's research focus includes pharmacoepidemiology and pharmacogenomics, and he is internationally known for his work in molecular cancer epidemiology and cancer risk prediction.


text:
Clayton County Parks and Recreation: Recreation Services
Clayton County has three recreation facilities that you can use for after school programs, fitness classes, dance classes, martial arts, swimming, basketball, arts and crafts, and more!
College Park Recreation Center
College Park's Recreation Center has tennis courts and walking trails, and also offers special programs such as aerobics, youth basketball, youth baseball, cheerleading, dance, karate, and youth tennis.
Forest Park Recreation & Leisure Services
The City of Forest Park has a Recreation Building and an 18-acre park with a tennis court, a sand volleyball court, a stage, an outdoor pool, a mini-golf course, baseball fields, horseshoe pits, a walking/jogging path, picnic areas, concession stands, and a football stadium.

subset: commoncrawl


text:
Users Online Now:
Who's On?
Visitors Today:
Pageviews Today:
Threads Today:
Posts Today:
Join Our:
GLP Poker Rooms
Donate To GLP
Adv. Search
Back to Forum
Back to Thread
Message Subject
Proof you will live this exact same life over and over again for all eternity
Poster Handle
Post Content
yeah i used logic to think this out as a kid.. there cant be a start and an end to time, something cant come from nothing, so something allways has to have been there, and it could just as well be something as nothing...
Anonymous Coward 41633730
In the absence of anything, in utter nothingness, there is only the potential. Everything that *can* be, every potential kind of reality, the infinite number of possibilities. In this infinite primordial soup of concepts and worlds, there is one possible world where conscious observation of electromagnetism collapses waves of potential into particles of real. As this imaginary universe plays itself out among the other imaginary universes, in a quantum flux of never being real or unreal, it eventually gets to a point where it creates conscious life forms that can observe it. Upon observation, this fictional reality with these particular properties collapses all of it's potential waveforms from their states of quantum flux into actual particles, with measurable positions and velocities, and the universe emerges, already billions of years old.
Cliff Notes version:
In the absence of what is, there is everything that can be. One of these things that can be, is a universe that creates itself...so it does. And here we are.
Please verify you're human:
Reason for copyright violation:
Adoption/Child Welfare Bill H.R. 4980 Passed By Senate, Heads to President
4Chan strikes again by tricking gullible iPhone users into charging their phones in the microwave
A slow-motion disaster in the making for Sunshine State
BOMBSHELL: DHS Forced to Admit to Terrorists Caught at Texas Border
New Evidence Confirms Columbus had Map
The CDC, NIH & Bill Gates Own the Patents On Existing Ebola & Related Vaccines
Public University Requires Students to Submit Their Sexual History.
What a Dental Hygienist Found in Her Patient's Mouths Forced a Company to Take Action
Satanists Handing Out Religious Literature at Schools
Comcast Denies It Will Cut Off Customers Who Use Tor, The Web Browser For Criminals
Expect the Unexpected: More 9.0 Megaquakes Are Coming, Study Says
Foreign-Born Population to Reach 60 Million Within 10 Years.
Ebola Outbreak could last years..
DEVELOPING – Odile Poised to Bring Catastrophic Flooding to Southwest.
CDC whistleblower: behind the media blackout
UK School Using Biometric Fingerprint Data to Make Sure Kids Eat 'Healthy Diet'
Now we come to vaccines and depopulation experiments
Nationwide Biometric Database Goes Live
New Emergency Drills Simulate Nuclear Explosion In Nebraska
The Number Of Volcanic Eruptions Is Increasing And That Could Lead To An Extremely Cold Winter
The Smoking Guns of the 2001 Anthrax Attacks
School to fingerprint students to 'monitor their diets'
Los Angeles Unified School District's Armored Vehicle and Grenade Launchers
Federal government may seize and shut down all internet sites that don't push vaccines during a national emergency pandemic
ObamaCare Contractors Paid To Play Pictionary
We're dropping truth bombs like it's the end of days!
Disclaimer / Copyright Info
Privacy Policy
Terms Of Use
with questions or comments about this site.
"Godlike Productions" & "GLP" are registered trademarks of Zero Point Ltd.
Website Design Copyright © 1999 - 2014 Godlikeproductions.com
Page generated in 0.008s (3 queries)


text:
There's something about watching Olympic athletes that makes you want to get off the couch and go break a world record.
Well, maybe not a world record. But at least run around outside.
Which is why Patch is excited to be joining with First Lady Michelle Obama for Olympic Fun Day. The first lady is leading the U.S. Olympic delegation at the Summer Games opening ceremonies in London on Friday July 27. Her fitness initiative, Let's Move, and Patch are teaming up to bring Olympic sports to life for you and your family in your town. Here's how:
1. If you (or anyone you know) are interested in trying an Olympic sport, check out Partnership for a Healthier America's website, where you can track down professionals who offer instruction in your region in everything from swimming to cycling to track and field.
2. You can find local Olympic Fun Day events on the First Lady's Let's Move website, which right now has a great page about how to set up your own local Olympics, full of fun and fresh air!
3. Check out our Directory and Events Calendar - we have listings for places that teach everything from karate to weight training. In our calendar of events, you can find day camps where you could learn archery or play soccer. Or if you are looking for a great venue to watch events that are more fun with a crowd, check out our listing of great local sports bars.
And don't forget to go for the gold!


text:
If you believe this comment is offensive or violates the CBSNews.com Terms of Use, you can report it below (this will not automatically remove the comment). Once reported, our staff will be notified and the comment will be reviewed.
Select type of offense:
Spam: Advertisements, commercial links, or repetitive posts
Disruptive posting: Flaming or offending other users
Illegal activities: Promote cracked software, or other illegal content
Off-topic: Commentary unrelated to the storyline
Comments (optional):
E-mail this to:
Your e-mail address:
Note: Your e-mail address is used only to let the recipient know who sent the e-mail and in case of transmission error. Neither your address nor the recipients's address will be used for any other purpose.
Add your own personal message: (Optional)


text:
Fayman Archive
Collections Management: The Internship
This week, MOPA's Curatorial Department is pleased to present a guest blog from our summer intern, Diana Chavez. Read on to learn more about her adventures in Collections Management.
~ ~ ~ ~ ~ ~
Fayman Archive: Sorting Things Out
Even as a kid, I loved to sort things. I know, it seems a strange thing to enjoy, but I lived for sorting. I always found it to be deeply satisfying to see a perfectly organized group of things, whether they were toys, books, or the clothes in my closet. Simply put, organization is one of the most essential elements of collections management for all museums.
A Treasure Hunt
This week, we will be featuring the thoughts of Jerry Gardner, one of the Curatorial Department's volunteers, on his work with the Fayman Archive.
Fayman Archive Comes to MOPA!
For a Collections Manager, getting a new collection is a bit like Christmas. The anticipation builds each day as you prepare to bring the boxes of items to the museum. Then, you feel the excitement of getting to unpack each one and discover the treasures inside. Finally, a feeling of satisfaction as you survey all of the wonderful things that will soon be housed in the museum's collection. Happily, for those of us in the Curatorial Department, we've gotten to experience all of these emotions over the past few weeks as we inventory MOPA's most recent acquisition: the


text:
Cambridge Junior College
has short-term programs and flexible schedules to fit your needs. Find out more »
has short-term programs and flexible schedules to fit your needs. Find out more »
are available to qualifying California students who attend Cambridge Junior College. Find out more »
offers the career training you need to be successful and the potential to improve your life! Find out more »
@CambridgeJuniorTweets by @CambridgeJunior
We'd love it if you were here. Use our contact form and we'll let you know more about what's happening here at Cambridge.
If you are searching for Yuba City and Woodland colleges that can help you prepare for a new career in a shorter amount of time, we encourage you to learn more about Cambridge Junior College. We strive to provide you with the training you need to pursue a successful career in healthcare or business. Our business and healthcare degrees allow students to begin preparing for careers in growing fields.
Why should you choose Cambridge Junior College over other junior colleges in California? We're passionate about helping you succeed. We believe our graduates are a valuable part of our local economy. We want to see you pursue your professional goals and make a difference in the community around you. Our programs offer hands-on learning and practical skills that you can apply to your future career. Industry-experienced instructors are happy to provide you with individual attention and support as you work through training to become a medical receptionist, medical assistant or business professional.
Upon completion of your program, our career services department will help you get a strong start on your career search. We can review your resume, help prepare you for interviews and assist you as you search for potential career opportunities. Financial aid is available for all of our programs for those who qualify.
If you're interested in earning a business administration degree or finding a medical receptionist school in the Sacramento area that can offer accelerated, career-focused training, look no further than Cambridge Junior College. Contact us today to see how Cambridge Junior College can help you earn the education you need to achieve your professional goals.


text:
Redskins-Jaguars gallery
Images from the Washington Redskins-Jacksonville Jaguars game on Sunday, Sept. 14, 2014
See the top 10 U.S. military helicopters of all time.
Images from the Washington Redskins-Jacksonville Jaguars game on Sunday, Sept. 14, 2014Shares
Ray Rice is just the latest famous athlete to draw the ire of the American public. Sports stars haven't always acted as role models — both on and off the field.Shares
The most prolific makes of handguns manufactured in the U.S., based on production statistics provided to ATF.Shares
See the 10 worst uniforms in pro football.Shares
See the wives and girlfriends of NFL stars.Shares
See the best rivalries in college footballShares
Vacation spots frequented by US PresidentsShares
A list of political figures who've been imprisonedShares
See the best party schools in the nationShares
The Nationals have shown a knack for coming through with the clutch hit late in gamesShares
See the biggest celebrity divorce settlements.Shares
See the top 10 U.S. military helicopters of all time.Shares
Washington Times photographer Andrew Harnik captures the summer season in the DistrictShares
Stunning photos of the biggest and brightest full moon of the yearShares
See the demonstrations that changed our nationShares
See the sports stars with conservative ideals.Shares
Politicians with famous look-alikes.Shares
See police booking photos of stars that broke the lawShares
Stars who went from entertaining fans to public service.Shares
Sports stars who tried their hand at acting — with mixed results.Shares


text:
Turn subtitles on
Turn subtitles off
Play all
Unique functions - PCC (This film shows V70 MY09)
26880:30902|You can have one of two different key systems, the key and remote control
31033:33593|or the Personal Car Communicator.
38478:41404|The PCC has some really clever functions.
41769:45400|When you are in range and press the I-button the car communicates with you.
46315:48000|Green light means the car is locked.
48248:50703|The yellow light says it's unlocked.
51800:54439|This red light indicates the alarm has been triggered.
55144:58435|And if the red lights are flashing, there may be someone in the car!
Keyless drive (only PCC)
1960:5146|Any key system can be equipped for keyless drive.
5303:9091|You will appreciate this feature even before you enter the driver seat.
11808:15282|With the keyless drive all you have to do is approach the car.
17346:22831|With the remote in your pocket, the car recognize you when you enter a 1,5 meter radius.
25240:27899|And the doors unlock instantly when you pull the handle.
Steering wheel
1147:4296|The first thing you want to do is to adjust the steering wheel.
5080:9233|Just pull this lever and adjust the wheel up or down, in or out.
9546:14980|Then you will adjust your seats. This is a little different depending on what seats you have.
15084:18480|Please show me if you have a manual seat or a power seat.
Mechanical seat
0:2403|You have chosen the manual seats.
2821:8150|Adjustment is really simple. Just pull this bar to move it forward or backward.
10710:17867|Raise or lower the front of the seat by pulling up or pressing down on this and move the backrest with this.
18468:21289|Move the seat up or down with this handle.
23144:25704|The lumbar support is adjusted here.
Seat with memory function*
391:4257|You have chosen the optional power seats with three memory settings.
4680:11023|Adjustment is really simple. Just press this button to move the seat forward or backward.
12016:16509|Raise or lower the seat with this, and move the backrest with this.
17711:19931|Move the front of the seat cushion with this.
20880:24215|Store your setting by pressing the memory button and setting 1.
24737:28160|The lumbar support is adjusted here. That's it.
28360:32156|Now, this setting is activated every time this key and remote is used.
32444:35526|This means you can have individual settings for different keys.
36623:39784|It's really convenient if you share the car with someone else.
Starting the engine
21916:25861|With the keyless drive you can keep your key and remote in your pocket
26148:29675|and all you have to do is to press the brake and press the starter button quickly.
30850:34324|Starting is just slightly different if you don't have the keyless drive.
34455:39810|As you can see there is a slot beside the start button. That's where you insert the key, like this.
41586:45165|It unlocks the steering wheel and powers up the radio if it's on.
45635:49266|To remove the key you simply press it again and it ejects.
51043:53786|Start the engine by pressing the brake and the start button.
54648:58226|To stop the engine, just press the stop button until the engine stops.
High idle speed
444:2063|Listen to the high idle speed.
2324:7732|When you hear the engine revving at cold start it's a feature that makes the exhausts cleaner and less harmful.
8385:10788|This can go on for several minutes if it's really cold.
Driver's door control panel
1201:6295|You can lock all the doors including the trunk from the inside by pressing this button.
6635:12564|Unlock by pressing again. The power windows can be controlled from the driver side.
13635:18416|A full press or pull opens or close the window automatically all the way.
18964:22491|A gentle press or pull gives manual control.
Parking assistance*
38:5642|I know some people don't like parking in tight spots, but the park assist makes a big difference.
6217:7678|I'll put the gear in reverse.
8176:13688|The park assist has a display in the center console showing you where an obstruction is detected.
14288:19226|When the obstruction bar becomes solid you are within 30 cm of the obstacle.
20453:25573|We hear a pulsing tone from the rear speakers, indicating an obstruction behind the car.
25998:31085|And it's within one point five meters. I'll back up and you should listen.
32104:37877|When it changes to a solid tone we are 30 cm from the obstacle. That's close enough.
Electronic climate control, ECC*
1671:6452|The climate can be controlled automatically by pressing the Auto button.
8489:12721|You can set the temperature individually for the driver side or the passenger side.
14158:17371|Just turn the knob on the side where you want to set the temperature.
18808:22700|To override the blower Auto setting, turn the blower knob.
23614:27454|Change the air distribution by pressing one of the buttons in the symbol.
27977:32638|The air quality button toggles between Recirculation, Auto or Off.
33567:37720|If you always leave the air conditioning on, it makes the air quality better
37929:40437|and it quickly removes condensation from the windows.
Rain sensor (option)
1436:5198|It's a good idea to always activate the rain sensor when there is a risk for rain.
5668:7862|This way you don't have to bother with the wipers.
8672:13583|There is even a symbol in the main instrument for it. Makes it easy to see if it's on or off.
15777:19918|You might want to make an extra wipe now and then. Just flip the stalk upward.
20297:25182|But if you flip it downward you override the rain sensor and you have to activate it again.
Audio system
992:3395|The sound system in this car is impressive.
4257:9769|You have a Dolby Prologic II decoder for true surround effects from CD and MP3.
10657:15020|You can plug in your mp3 player in the auxiliary input and listen through the speakers.
16404:19435|The first time you might need to adjust the input volume.
20532:22838|Just press the Mode button and then turn the volume knob.
24685:29048|If you switch to the CD player or the radio, they can be controlled from the back seat.
30902:36806|From the back seat they can change tracks or stations, go fast forward or backward or seek stations.
39627:41952|Another smart feature is the Soundstage.
43755:48822|It is used to optimize the sound for the driver's seat, both front seats or the back seat.
53603:56711|The steering wheel buttons control the radio and CD.
57364:61718|With a short press on the forward button you change preset radio station or CD tracks.
63320:67631|Press and hold to fast forward the CD player or search for radio stations.
67709:71235|The Volume control is simple just up or down.
Clock and trip meter
1828:3996|Let's have a look at how to set the clock.
6817:10501|You set it by turning this knob left or right. That's it.
12382:15124|The same button is used to set the two trip meters.
15412:21002|A short press toggles between the two. A long press reset the current trip meter.
Trip computer
1332:6112|In the center of the displays you have information about fuel quantity and outside temperature.
6556:11337|This display is also used when setting the adaptive cruise control and using the trip computer.
13583:17293|You find the trip computer by turning the outer wheel on the left stalk.
19565:25260|There is one function that you might want to know more about, the distance to empty tank.
26044:31059|The distance is calculated from the average fuel consumption during the last 30 kilometers.
31294:35970|This means that if you start driving more aggressively it might not be totally accurate.
Storage compartment
1238:7026|Lets take a look at the convenient storage compartments. There is one beneath each front seat.
8986:15307|Then there's the CD storage in the center. You can actually fit 15 CD:s in there if you use it right.
17345:20976|Small objects can be placed behind the centre stack, out of the way.
21942:26671|Then of course the side pockets, seat pockets and cup holders.
Electrical sockets
1018:4257|There are three electrical 12V sockets in the car.
5015:12486|One in the center console, one in the back seat panel and one in the cargo compartment.
Automatic tailgate control*
15360:19226|The optional Power Operated Tailgate can be opened in three ways.
19774:22125|By pressing the button in the light panel.
22595:27663|By pressing the button on the key and remote or by pulling the tailgate handle.
30249:34586|The tailgate can be closed manually or by pressing the button on the rim.
1462:5825|At times you may want to transport long objects. It's easily done.
6844:9299|Just fold the backseats by pulling these handles.
10971:14027|You can fold the left and middle section separately.
18259:22491|The right backseat can only be folded together with the middle section.
Floor panel
1488:5250|Fold up the floor panel to reach the storage compartment underneath.
6687:9795|This is a good place for the warning triangle and a first aid kit.
Load fixation hooks
1253:7444|The load fixation hooks can be moved. Fold the hook, move it to the new position and fold it back.
7706:9142|It locks automatically.
Cargo cover
1175:4414|Put the cargo cover with both ends in the holders on the sides.
4675:7418|Press the cover downward until it clicks in place.
10187:13844|Pull out the cargo cover and hook it into the recesses in the rear pillars.
Blind Spot Information System, BLIS*
2638:7680|The Blind Spot Information System is an option that will help you to notice vehicles in the blind spot.
9090:17214|When someone enters the blind spot either from behind or when you overtake someone, you get a warning light here.
Direction indicators
1541:8097|The direction indicators have a short flash option with three flashes if you move the stalk switch up or down one step.
8777:10318|This is perfect when overtaking.
Light controls
888:4545|Turn the headlamp control clockwise to the end position for running lights.
5929:9456|Flash the main beam by moving the stalk gently towards the steering wheel.
10945:14184|In the lighting panel you can also adjust the height of the light beam.
15490:19226|Do this if the car is heavy loaded and the beam points too high.
914:6034|When you fill petrol (gas) you will have to open the fuel cap cover from inside the car.
6321:7627|It's done right here.
8855:14158|There is also an indication in the main instrument showing that the fuel cap is located on the right side of the car.
287:4571|To use a child seat in the front seat, you MUST deactivate the passenger airbag.
6452:9116|To do this, open the door and turn the switch to OFF.
10919:16457|A text message in the overhead consol will be shown that indicates that the airbag is deactivated.
Integrated two-stage booster cushions*
235:3291|When your children has grown out of the rear facing child seat
317:7053|they should use the optional 2-Stage Booster Cushion in the backseat.
7862:11278|The Booster Cushion can be adjusted in two heights to accommodate children
11546:19017|between 95 and 120 cm tall and between 115 and 140 cm tall.
19200:25391|To set level one, pull the handle forward and up. Press the cushion backward to lock.
25913:30876|To set level two you must start from level one. Press the button and lift the cushion up.
31817:38086|Press it backward to lock. Note that you can not shift from level two to level one.
40176:44042|To fold down, pull the handle forward and press down.
Leather care
1358:6373|Over time the protective surface on leather upholstery may be dissolved by grease and dirt.
6896:12512|It is a good advice to use Volvos recommended leather´s cleaning products to regain the leathers protective layer.
Paint care
3604:7706|Volvos paint experts want to help you to take good care of your new car
7784:11363|and say that it's best to hand wash the car during the first months.
Designed for adventure, spontaneity and freedom
The Volvo XC70 is a cross-country vehicle designed for adventure, spontaneity and freedom. It is a luxury wagon uniting safety with comfort and one of the most advanced chassis in the world. Whether you drive on forest tracks or open highways, the XC70 gives you precise handling, fast steering response and optimum roadholding.
Introducing your VolvoThis film offers you a comprehensive and inspirational overview of your Volvo – how to operate the vehicle including visual guides to unique features and functions.
Downloadable Owner's Manual and Quick GuidePlease note that the printed Owner's Manual and Quick Guide supplied in your car have the most up-to-date information for your specific vehicle.
Volvo SelektTo search for Volvo XC70 Selekt used cars click here.


text:
Join the Girl Scouts in celebrating their first hundred years! This uncirculated 2013 Girl Scouts of the USA Centennial Silver Dollar is struck on special presses using greater force than circulating coins, producing a sharp, intricately detailed image.
The obverse (heads side) design was inspired by both the historical and contemporary aspects of Girl Scouting and by its mission statement: "Girl Scouting builds girls of courage, confidence, and character, who make the world a better place." It depicts three girls who represent the different ages and diversity of Girl Scouts of the USA. Inscriptions include COURAGE, CONFIDENCE and CHARACTER, key elements of the Girl Scouts mission statement. The 100th anniversary Trefoil symbol signifies the centennial anniversary. Additional inscriptions are 2013, LIBERTY and IN GOD WE TRUST.
The reverse (tails) design depicts the iconic Profiles of Girl Scouts of the USA with the inscriptions UNITED STATES OF AMERICA, E PLURIBUS UNUM, $1 and GIRL SCOUTS.
The Girl Scouts organization was established on March 12, 1912, by Juliette Gordon Low in Savannah, Georgia. It was chartered by the U.S. Congress in 1950. Today, there are more than 3.2 million girls and adult leaders throughout the U.S. and its territories. Members of Girl Scouts of the USA are part of an international family of 10 million girls and adults. Today, it is the world's pre-eminent leadership organization dedicated solely to girls, building character and skills for success.
Mintage Limit: 350,000 (across all product options)
|Specification Name
|Specification Value
|Coin Specifications
| 90% Silver,
10% Copper
| 26.730 grams
| 1.5000 inches
(±0.003) or 38.10 mm
|Mint and Mint Mark
|West Point - W
On-Sale Date: To ensure that all members of the public have fair and equal access to United States Mint products, any order placed prior to the official on-sale date and time of February 28, 2013, at 12 noon (ET) shall not be deemed accepted by the United States Mint and will not be honored. This product will be available during 2013 only.
Credit Card: If paying by credit card, please be sure your credit card information remains current to avoid any delays in processing your order. If your credit card has expired by the time of shipment, your order will be cancelled. To update credit card information after an order has been placed, you must call 1-800-USA-MINT (872-6468).
Shipping: Please allow one to two (1-2) weeks for shipping of in-stock products.


text:
The CM 930 B microphone head is suitable for vocals and speech application. Due to its cardioid polar pattern, it features a high gain-before-feedback and achieves a superb audio quality and excellent intelligibility of speech.
* Required Fields
Jim Reinhardtbeyerdynamic Inc. USA56 Central Ave.Farmingdale, NY 11735Phone +1 (631) 293-3200E-mail
UHF handheld transmitter for Opus 910 wireless systems, plastic housing, with charging contacts
Battery-powered version - SLG 900 charger is required.


text: Tell your DH next time to put a warm cloth on the area and sit in a steaming shower for a bit before - it opens the pores. After he's done he should put a cold cloth over top of it to close the pores! Works wonders with those little red, itchy bumps!


text:
Someone who has trouble playing with the Nintendo Wii. Someone who breaks something with the Wiimote.
He broke the T.V. with the Wiimote. He is Wiitarded.
by Billeh1234 November 29, 2006
A label used to define an individual that is incapable of playing a Nintendo Wii with any amount of skill. Their coordination and kinetic abilities are so insufficient that they are laughed out of any Wii playing session.
" Hey! Gary hit himself in the balls with the Wii-mote again! He's so goddamn wiitarded. "
by J Lau December 22, 2006
The act of getting down with the Wii until it gets Wii-Tarded up in here.
Grant: Yo nigs, where you at?
Patrick: I'm getting Wii-Tarded!!!!!
Grant: Shit is mad gay.
Patrick: Nu-uh you're gay.
Patrick: I'm getting Wii-Tarded!!!!!
Grant: Shit is mad gay.
Patrick: Nu-uh you're gay.
by Gpopper. March 04, 2010
using other system's controllers like a Wii-mote
Dude, you look Wii-tarded waving that Xbox360 controller around.
by Marcus White November 27, 2007


text:
|1 of 3
small (250x250 max)
medium (500x500 max)
large ( > 500x500)
Full Resolution
All (PDF)
This page
Loading content ...
Reign Over Homecoming Homecoming Queen Carol Huss and attendents Shirley Chambers and Bonnie Scott (above) reigned over the Weber college Homecoming. Photo by U. Akisada. Homecoming Day See Grads Return to Weber Campus Nearly 200 former Weber college students returned to the campus and the old memories it possessed Friday, October 24, to give the college one of its most successful homecoming celebrations. The annual event, designed to keep college memories living, started with the homecoming assembly in the Moench auditorium on Friday and continued through the day with banquets, parades, and rally, and was climaxed with the homecoming dance in the college ballroom. Assembly Held Highlights of the morning assembly were furnished by Dr. Henry Aldous Dixon, president of Weber college, with an amusing series of memory sketches, and by the crowning of the Homecoming queen, Carol Huss, and her two attendants, Shirley Chambers and Bonnie Scott. The football team were the recipients of a beautiful cake presented by the Whip club, with Bonnie Parker making the presentation. Humorous acts put the cap on the assembly, which was followed by a snake dance and pep rally in downtown Ogden. Parade Tours City A large homecoming parade toured the city during the afternoon, 25 organizations participating with floats. The annual alumni banquet was held at 530 pm in the college cafeteria, with the college music department furnishing entertainment for the many former students in attendance. Blaine Corey was toastmaster for the event, and E. Ray Wilkinson, alumni president, was in charge of the affair. Game is Highlight. Highlight of the day was the Weber Compton football game in Ogden stadium Friday evening. Whip club�s precision drilling and judging of the floats occupied the half time. Taking prizes for the best floats were Excelsior, Viking, Phoenix, Otyokwa, La Dianaeda and Sigma Delta Pi, in that order. The day was climaxed by the homecoming dance in the college ballroom, over which the homecoming queen and attendants presided. Hawaiians Capture College with Island Color and Spirit. Greet Hawaiians Greeting Coach Bill Baker (left) of the Mickalums squad, scheduled to play the Wildcats Friday evening, are Henry Aldous Dixon, President and Reed K. Swenson, Athletic Director.
Object Description
|Weber College
|Weber College; Whip Club
|This Collection consists of a 119 page Scrapbook put together by members of the Weber College Whip Club, the school's pep club, covering the years between 1946 and 1955. Included are a full listing of yearly pledges, 27 football programs, newspaper clippings concerning charity and sports events, 10 invitations, menus, 7 letters, 15 photographs, and a biography of the Whip Club by Norma Manning.
|Date Original
|Physical Description
|Brown Leather 11 in. X 14 in. 119 page Scrapbook
|Ogden (Utah); Weber College; Weber State College
|Digital Format
|image/tiff; image/jpg; application/pdf
|Publisher Digital
|Stewart Library, Weber State University
|Date Digital
|Text; Image
|Weber State University Archives
|Conversion Specifications
|TIFF images were scanned by Jacqlin Guernsey and Jill Walker at 400 dpi with an Epson Expression 10000XL scanner. JPG and PDF files were then created for general use.
|Digital Identifier
|Rights Management
|Materials may be used for non-profit and educational purposes; please credit University Archives, Stewart Library, Weber State University.
Add tags for 000
Post a Comment for 000


text:
We've had a couple moments during this trial
that have reinforced the importance of setting the right priorities in our
lives – you know, those precious few hours that DON'T involve sitting on hard
benches and trying to make sense of the work of lawyers who seem like their
idea of a good time is finding a cat in the dark and arguing over which shade
of gray it is.
The first reminder occurred last month in the
courtroom, when attorney Gerald Evelyn – a workaholic with a reputation for
putting his clients' needs ahead of even his own physical well-being – fell
ill. Thankfully, his collapse identified a treatable condition while providing
an indisputable warning that he needs to take better care of himself. He's back
in court, back on top of his game and, hopefully, squeezing in a few hours
sleep on a regular basis.
The second reminder occurred this week and is
more subtle, coming in the form of narrow, elastic black bands wrapped
around the badges of court security officers throughout the courthouse.
The bands honor their brother, Mike
Jastremski, a tall, quiet man with a fondness for word games and
He reportedly also had a keen eye for stray bottles
and cans (and their 10-cent bounties).
His tidy appearance was betrayed only by the
unruly strands of wiry gray hair on his pate, which gave rise to good-natured
ribbing and the nickname "Kramer." He was also known as "Fish," for his vague
resemblance to Abe Vigoda, who played Det. Phil Fish on the 70s and 80s police
sitcom "Barney Miller" and the short-lived spin-off "Fish." (Vigoda also
starred as Tessio in "The Godfather," the film Kwame Kilpatrick and Christine
Beatty discussed in their infamous text messages.)
Jastremski went home from work last week and
didn't come back. He died in his sleep on Thanksgiving.
His colleagues say he had no family, but it
sure seems like he had plenty of friends.
CSOs spoke glowingly of a kind, shy man who
had plenty to say, if someone engaged him.
His gentle nature even made an impression
on some of the reporters who were regulars in the courthouse even before the
former mayor, his father and their good friend Bobby Ferguson became
regulars in the courthouse, too.
While Jastremski at some point in his life
apparently expressed a preference that no one make a fuss over his passing – he
will be cremated and there will be no formal services – his colleagues will
celebrate his life Thursday evening at a local establishment. The agenda, like
the honoree, will be focus on the simple things in life: food, beverages,
I didn't know Jastremski at all. We both sat
in the media room once, maybe twice, during the Kilpatrick Inc. trial. I don't
recall whether we ever exchanged more than a polite nod.
But I know this much: Even people who live
quiet lives, whether they realize it or not, touch people.
And while they may pass without a word, there
are people who will miss them and speak well of them.
To me, that's as fine a tribute as any I
can imagine.
Follow M.L. Elrick's coverage of the
Kilpatrick & Co. trial daily on FOX 2 and at www.myfoxdetroit.com. Contact him at email@example.com or via Twitter
(@elrick) or Facebook. And catch him every Friday morning around 7:15 a.m. on
Drew & Mike on WRIF, 101.1 FM. He is co-author of "The Kwame Sutra:
Musings on Lust, Life and Leadership from Detroit Mayor Kwame Kilpatrick,"
available at www.kwamesutra.com. A
portion of sales benefit the Eagle Sports Club and Soar Tutoring. Learn more at
WHBQ-TV | Fox 13 485 S. Highland St.Memphis, TN 38111Main Station: (901) 320-1313Newsroom: (901) 320-1340


text: The crowds were excited by the healings as well as delighted with Jesus' stories. Even though they didn't fully understand all they heard, they were drawn to the Speaker. "And there went great multitudes with Him" Luke 14:25. Knowing that the majority had no idea what was involved to be a true follower, He startled them with "If any man come to me, and hate not his father, and mother, and wife, and children, and brethren, and sisters, yea, and his own life also, he cannot be my disciple.Subscribe to Read!


text:
- News
- Weather
- Sports
- Community
- Features
- Programming
- Station Info
- Featured on 4
Thursday, February 14, 2013 - 11:52pm
(CNN) — President Barack Obama and first lady Michelle Obama shared a Valentine's Day dinner at an upscale Washington restaurant Thursday evening.
The first couple dined at Minibar, a restaurant in the district's Penn Quarter neighborhood that sits only 24 guests per night and where the window for reservations opens at least a month in advance.
The restaurant's website says the prix fixe menu is $225 per person. The restaurant is open only three nights a week.
The last time the Obamas went out to dinner on Valentine's Day was in 2009, when the recently inaugurated first couple spent the weekend in their Chicago home and dined at Table 52, a restaurant owned by Oprah Winfrey's former chef.


text:
The Key To My Heart
Banner by: Molly Greeves
Isabella Swan and Emmett Swan are the new students at Forks High. There are lots of Casanova's in the school, and they use all the girls at the school. They are actually used to getting any girl they wanted. Isabella happens to become bait at the school because she is beautiful and new. Edward Cullen, the captain of the football team is one of the Casanova's, actually he is the leader. Bella becomes best friends with Edward's sister and she tells her everything about her brother. Bella has a necklace of her deceased mother Renee and she wears it all the time… Emmett and Alice then come up with the idea of a Challenge for the guys… They are still interested in her after a few weeks and accept… What will happen????
Looking for something to read? Check this out!
A Twist Of Life
Banner by: Molly Greeves
This story happens in the time when Bella has to choose between Edward and Jacob. The whole Twist in this story is that Bella doesn't choose Edward, she chooses Jacob instead... Why? Because Bella has for some reason found a certain love for kids after she drives past a daycare and sees the mothers and kids hugging and kissing each other... Bella then thinks she can't have kids with Edward, so she chooses Jacob. That was the hardest decision she ever had to make, but Bella went with her mind instead of with her heart. Bella then marries Jacob, has kids and is having a wonderful life.
After five years-(which then makes Bella 23 years old)- the Volturi went and checked with the Cullen's to see if Bella was still human, and to their surprise Bella is not even with the Cullen's anymore. That to them is danger because Bella could reveal their secret. They then find out where she is and go to kill her. That forces the Cullen's to go and protect Bella and to let her know what is coming for her, because Edward just could not stand anyone hurting Bella because he obviously still loves her.
What will happen then, after Edward hasn't seen Bella for five years and still loves her and Jacob feeling very protective of his family...
Click Here to Read A Twist Of Life:) and It's sequel Soul Erosion:)
Thanks for reading.
I appreciate every read, comment and tip to better.
Views: 6786
Love the update! Glad they finally got to talk and that nothing happened.
*Dancing around the house* They finally kiss
Gosh finally I was bout to lose hope lol. This is great.
The only thing is left is Rosalie....I think.
Keep me updated.
AWWWWWWWWW!!!!!!!!!!!!!!!!!!!!!!!!!!! How cute!!!!!!!!!! Please dont let Edward hurt her again!!!!!!!!!!!!!!! More soon though please!!!!!!!!!!!!!!!!!!
They are so cute together!
© 2014 Created by Hachette Book Group.
Report an Issue | Guidelines | Report an Issue | Terms of Service


text:
A.F. Branco turns DNC chief's comment back on herself
Rick McKee illustrates Obama promise to Liberia
Mike Lester illustrates nature of ruling barring U.S. flag shirt on Cinco do Mayo
A.F. Branco illustrates latest footwear issued to GIs
Mike Lester has president collecting signatures for anti-ISIS coalition
A.F. Branco has Nancy Pelosi donning sandwich board
Nate Beeler has man seeking notarized document from woman
Can Cardow illustrates Obama's response to ISIS' numerous beheadings
Mike Lester illustrates nature of president's controversial ISIS claim
Nate Beeler illustrates Obama's path to his teleprompter


text:
Replacement plastic footwell for the feet of the child on board the main seat of your vibe 2 buggy.
Not currently available in this region.
This footrest can be replaced using a standard screwdriver. It is compatible only with vibe 2 buggies.
Please note: reviews will not be made public until they have been scrutinized to omit objectionable material
Your privacy is important to us, personal details are used for phil&teds purposes only.
Privacy policy
Thanks %user_name%
Your review has been sent for 'review'!
Want to receive updates about new products and promotions?
© 2014 philandteds.com


text:
The body of a Smith County man who was reported missing about two weeks ago has been found in Anderson County.
On September 10, Adam Palacios was reported missing by his sister, Amy.
She told officials it was not uncommon for Adam to leave the area for several days without communicating with friends or family. However, Amy told officials he had been gone longer than normal.
At that time, Adam was listed as an official missing person.
Smith County Investigators began their search for him.
Continuing to follow leads, investigators discovered Adam's body in a remote area in Anderson County.
Due to the condition in which his body was found, the cause of death has not yet been determined.
Both Smith and Anderson County Sheriff's Offices are working to apprehend the person or persons responsible for Adam's death.
Copyright 2012 KLTV. All rights reserved.
730 North Summit Street
Toledo, OH 43604
FCC Public File
EEO Report
Closed Captioning
FCC Public File
EEO Report
Closed Captioning


text:
The Resource Finder has powerful filtering features — check out the tutorial to learn more.
Series: Evolution Basics (48 entries)
Written by BioLogos Fellow of Biology Dennis Venema, this series of posts is intended as a basic introduction to the science of evolution for non-specialists.
Origins News Roundup for August 6, 2014
News about the Ebola outbreak and initiatives in genomic medicine lead our news roundup this week, with a collection of research and learning opportunities in biology and at the science/faith border to follow.
What about the Bible?
What we do learn from scripture is that there is only one Creator and that there's a clear distinction between God and the created world. And that we who are created in the image of God are able to investigate a creation that is remarkably tuned for our discovery.
Origins News Round-Up for May 28, 2014
This weeks in Origins news: studies of a skeleton uncovered in 2007 provide clues about rapid human evolution in the Americas, our climate and Christian stewardship, a few BioLogos folks give interviews, and some cool links to miscellaneous finds.
Human Evolution: Genes, Genealogies and Phylogenies
When read in this way, the Genesis stories may be seen as one of the greatest-ever revolutions in human understanding. Genesis used the literary forms of the day to introduce its readers to a rational God who cares for people – and whose faithfulness made science possible. Genesis is expressly about theology, not science.
Origins News Roundup for May 14, 2014
This week in our Origins News Roundup: News of new nucleobases, the future of synthetic biology, and some healthy dialogue and critique of certain aspects of modern science.
Series: Intelligent Design and Common Ancestry (4 entries)
Would those genuinely interested in learning about evolution benefit from a careful explanation of why these common objections don't hold water? Here the answer seemed to me to be "yes."
BioLogos Basics Video #3: What about the Bible?
What we do learn from scripture is that there is only one Creator and that there's a clear distinction between God and the created world. And that we who are created in the image of God are able to investigate a creation that is remarkably tuned for our discovery.
"The Language of God" Book Club–Chapter 5
Does Collins show that Evangelicals have turned the corner on the scandal Noll brought to light, or does the continued resistance of the majority of Evangelicals to Collins's work (about 75% reject human evolution) show that we as a collective group still do not take the life of the mind seriously?
Origins News Round-up for January 17, 2014
Today's Origins News Roundup features challenging and exciting new ideas about evolutionary theory, fossil finds that add to our understanding of how carnivores and humans developed, some interesting science history from England, and more on American views of evolution.
Origins News Round-up for December 6, 2013
This week's Origins News Roundup features highlights from a recent conference of evangelical theologians, exciting human fossil finds, tell-tale lice, and a few words from the Pope.
Origins News Roundup for November 1, 2013
Where is human evolution going? Where has human evolution been? A roundup of stories from the past few weeks.
God's Extravagant Love in Creation
Critics of Christianity look to evolution to show how the emergence of human life on earth demanded enormous ruin and ravage, billions of years of apparent waste and futility, species extermination and organism road kill. Not only was the massive dying off rampant, it's mandatory too.
Series: The Evolutionary Origins of Genetic Information (4 entries)
Join astrobiologist Stephen Freeland for a look into the nature of information and the origins of life on earth. (These posts were originally published as a paper in the ASAs academic journal, PSCF, and are reprinted here with permission.)
Series: Excerpts from "Origins: Christian Perspectives on Creation, Evolution, and Intelligent Design" (7 entries)
These excerpts from Origins: Christian Perspectives on Creation, Evolution, and Intelligent Design, written by BioLogos president Deborah Haarsma and her husband Loren Haarsma, offer a sampling of the book's many topics, from exploring our disagreements and agreements on origins as Christians to explaining scientific processes to looking at how we read Genesis.
Biological Evolution: What Makes it Good Science? Part 2
The Galápagos Islands were not a distinct "center of creation," but a workshop for evolution in which an ancestral species made it to the yet uncolonized island and underwent a massive degree of speciation to adapt to the environment of the island. This is precisely what one would expect if the species of islands had arisen by evolution.
Meet Jimmy Lin, "Medical and Scientific Doxologist"
In our current culture, we're defined by our jobs. It's having a vocation. I wanted to shift away from that. I didn't want to be a doctor first and foremost, or a scientist, but one who praises God.
Series: Genes, Cells, and the Changing Face of Technology (2 entries)
BioLogos interim web editor Emily Ruppel recently traveled to Boston for the American Association for the Advancement of Science (AAAS) conference, where she took an afternoon off from lecture-going to catch up with Doug Lauffenburger, head of the biological engineering department at MIT and a member of the American Scientific Affiliation.
Hydrology of the Bow River
There's a word beneath the water, and the Bow River belongs to God. Have you been listening?


text:
Paul Lane doesn't feel that SE Oklahoma water should be sold to Texas & OKC area as its in the interest of SE Oklahoma economic development to keep it's water. He added that SE Oklahoma should have a voice on how its water is to be used, and that presently SE Oklahoma has NO say in the matter . Paul said that if elected he would file a companion bill w/state senator Brian Renagar (D-OK House District 17) status to make sure we have regional water boards, so that SE Oklahoman have a voice.
Lane's opponent who is GOP nominee Larry Boggs at this political candidate forum did not offer any solution , but he did agree w/ Lane's solution, but that SE Oklahoma had better vote for a Republican or we in SE Oklahoma will get no water rights because the republicans are in control.
The moderator's question posed to J. Paul Lane was: "The possible sale of SE Oklahoma water to Texas & Oklahoma City area still remains unresolved. What is your stance on selling SE Oklahoma water to Texas & OKC area & if there is anything you can do to reinforce what you think should or should not be done regarding the matter ?".
J. Paul Lane is the democrat nominee seeking election to the Oklahoma Senate District 7 that is being vacated by Richard C. Lerblance (democrat). Lane's opponent is Larry Boggs the Republican nominee. Election is November 6, 2012.
This political candidate forum was sponsored by McAlester News-Capital in McAlester, Oklahoma. This event was held on Oct 16, 2012 at 6pm at the Kiamichi Center in McAlester. Approximately 200 people attended.